

Cynomolgus IL-13RA1 Protein; His Tag

Product Information


Product Name	Cynomolgus IL-13RA1 Protein; His Tag
Storage temp	Store at $\leq -70^{\circ}\text{C}$, stable for 6 months after receipt. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Catalog# / Size	GM-88628RP-100 / 100 μg GM-88628RP-1000 / 1 mg

Protein Information

Alternative Names	CD213A1,IL-13Ra,NR4,RP13-128O4.2,IL13Ra1
Source	Cynomolgus IL-13RA1 Protein; His Tag (GM-88628RP) is expressed from human 293 cells (HEK-293). It contains AA Ala 25 - Thr 341 (Accession # XP_005594500.1). This protein carries a His tag at the C-terminus.
Purity	> 90% as determined by SDS-PAGE
Endotoxin	< 1 EU/ μg , determined by LAL gel clotting assay
Predicted Mol Mass	37.3 kDa
Formulation	Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4.
Description	IL-13RA1 protein, full name Interleukin-13 Receptor Subunit Alpha 1, is a cell surface receptor and a member of the type I cytokine receptor family. It binds IL-13 with low affinity and forms a high-affinity signaling complex by heterodimerizing with IL-4Ra. This receptor plays a critical role in regulating Th2-type immune responses, IgE class switching, and macrophage and epithelial cell activation. Aberrant expression or hyperactivation of IL-13RA1 is closely associated with inflammatory, fibrotic, and malignant diseases, particularly atopic dermatitis, asthma, and glioblastoma. Overexpression drives chronic inflammation, tissue remodeling, and tumor cell survival via JAK/STAT6, MAPK, and PI3K pathways, promoting disease progression and therapy resistance. Currently, several IL-13RA1-targeted therapies are under clinical development. Monoclonal antibodies such as Lebrikizumab and Tralokinumab, which block IL-13 binding, have shown efficacy in atopic dermatitis and asthma. Bispecific antibodies and ADCs targeting IL-13RA1 are also being explored for cancer treatment. In summary, IL-13RA1 is a valuable biomarker and promising therapeutic target, and its study is essential for understanding disease mechanisms and improving patient outcomes.


Version:4.0

SDS-PAGE



On SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

Bioactivity-ELISA



Cynomolgus IL-13RA1 Protein; His Tag (Catalog # GM-88628RP) was immobilized at 5 µg/ml (100 µL/well).

Increasing concentrations of Anti-IL-13RA1 hIgG4 Antibody (eblasakimab) (Catalog # GM-88181AB) were added.